AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

AIM ImmunoTech advances Ampligen with positive clinical data amid challenges

AIM ImmunoTech's Q3 showcased progress in Ampligen's development, with promising data supporting its therapeutic potential. While facing financial challenges, the company is focused on leveraging opportunities for collaborations and commercialization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Court Denies Jonathan Jorgl's Request for Preliminary Injunction; Finds that Jorgl Failed to Show Director Nomination Notice Complied with AIM's Bylaws and that Evidence Suggests Notice was Misleading

Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group's Nominations Valid

AIM ImmunoTech Board Issues Letter to Shareholders

Company expects to commence patient enrollment and dosing in Q1 2023 Company expects to commence patient enrollment and dosing in Q1 2023

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen® in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

AIM ImmunoTech Inc (NYSE:AIM) told investors it expects to begin enrolling patients in the first quarter next year for a Phase 2 trial of its investigational drug Ampligen as a therapeutic for patients with post-COVID conditions following regulatory approval. The US Food and Drug Administration (FDA) have cleared the firm's Investigational New Drug (IND) application for the drug AMP-518.

AIM ImmunoTech receives regulatory go-ahead for Phase 2 trial of investigational drug Ampligen for patients with post-COVID conditions

AIM ImmunoTech Announces FDA Clearance of IND Application to Evaluate Ampligen in Phase 2 Clinical Study for the Treatment of Post-COVID Conditions

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at 3:00 PM ET Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles Lapp of Hunter-Hopkins Center and Dr. Daniel Peterson of Sierra Internal Medicine on Wednesday, September 28th at 3:00 PM ET

AIM ImmunoTech to Present at the Virtual Investor Long COVID Event

OCALA, Fla.--(BUSINESS WIRE)--The Board of Directors (“Board”) of AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced that the Company has filed its Definitive Proxy Statement in connection with AIM's upcoming 2022 Annual Meeting of Stockholders (the “Annual Meeting”), to be held on November 3, 2022, and has mailed this statement, along with a letter, to shareholders. The full text of the letter follows. September 19, 2022 Dear fellow shareholders: Thank you for y

AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

OCALA, Fla., Sept. 07, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced that Thomas K. Equels, M.S. J.D. Chief Executive Officer of AIM, will present at the virtual H.C. Wainwright 24 th Annual Global Investment Conference being held in New York, N.Y., and virtually, September 12-14, 2022.

AIM ImmunoTech to Present at the H.C. Wainwright 24th Annual Global Investment Conference

OCALA, Fla., Sept. 06, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19, the disease caused by the SARS-CoV-2 virus, today announced Chris McAleer, Ph.D., Deputy Chief Science Officer of AIM, and William Mitchell, M.D. Ph.D., Chairman of the Board of Directors of AIM, will present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care being held at the Roswell Park Comprehensive Cancer Center in Buffalo, N.Y., September 8-10, 2022. In addition to management's presentations, the Company is proud to announce its sponsorship of the event.

AIM ImmunoTech Selected to Present at the 2nd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care

AIM ImmunoTech Inc (NYSE:AIM) said its clinical development collaborator Roswell Park Comprehensive Cancer Center has commenced patient enrollment in its phase 2 study evaluating Ampligen (rintatolimod) in subjects with primary PD-1/PD-L1 resistant melanoma. The company said the study, which is funded by the National Cancer Institute (NCI), will evaluate type-1 polarized dendritic cell (αDC1) vaccine in combination with tumor-selective chemokine modulation comprised of Interferon alpha 2b, Ampligen, and Celecoxib.

AIM ImmunoTech says study partner Roswell Park begins patient enrollment in Ampligen and resistant melanoma phase 2 trial

Phase 2 to evaluate polarized dendritic cell vaccine, interferon alpha-2b, Ampligen and celecoxib for the treatment of HLA-A2+ refractory melanoma

AIM ImmunoTech and Study Collaborator Roswell Park Commence Enrollment in an NCI-funded Phase 2 Clinical Trial Evaluating Ampligen® (rintatolimod) in Primary PD-1/PD-L1 Resistant Melanoma

AIM ImmunoTech Inc (NYSE:AIM) announced that its Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (LAPC) has commenced after its trial protocol received approval from an Institutional Review Board (IRB). The company's Phase 2 study Investigational New Drug (IND) application for Ampligen was previously cleared by the US Food and Drug Administration (FDA).

AIM ImmunoTech gets Institutional Review Board approval to begin Phase 2 pancreatic cancer trial of Ampligen

Company receives IRB approval of study protocol

AIM ImmunoTech Announces Commencement of Phase 2 Study of Ampligen® for the Treatment of Pancreatic Cancer

OCALA, Fla.--(BUSINESS WIRE)--AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, today issued the following statement regarding the outcome of a hearing in the Delaware Court of Chancery concerning a motion for a temporary restraining order (“TRO”) sought by activist shareholder Jonathan Jorgl: “This morning we announced in a

AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

AIM ImmunoTech Inc (NYSE:AIM) posted second-quarter financial results that showed ample cash on hand, giving the company scope to achieve multiple clinical and regulatory milestones. The Florida-based company's lead candidate Ampligen (rintatolimod), an immuno-modulator with broad spectrum activity, is being developed to treat multiple types of cancers, immune disorders, and viral disorders, including coronavirus (COVID-19).

AIM ImmunoTech ends 2Q well-positioned to achieve multiple clinical and regulatory milestones

– On track to commence Phase 2 study for lead program evaluating Ampligen® (rintatolimod) for the treatment of pancreatic cancer in Q3 2022

AIM ImmunoTech Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Aimia, Inc. (OTCPK:AIMFF) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Steven Leonard - CFO Philip Mittleman - CEO & Director Michael Lehmann - President & Director Conference Call Participants Brian Morrison - TD Securities Operator Good morning, ladies and gentlemen, and welcome to the Aimia Inc. Second Quarter 2022 Results Conference Call. [Operator Instructions].

Aimia, Inc. (AIMFF) CEO Philip Mittleman on Q2 2022 Results - Earnings Call Transcript

AIM ImmunoTech Inc (NYSE:AIM) has announced what it calls positive preliminary pilot study data from its ongoing Expanded Access Program (EAP) evaluating its investigational drug Ampligen as a therapeutic for Long COVID. The immuno-pharma firm said the preliminary data from this uncontrolled clinical trial found that patients reported statistically significant improvements in chronic fatigue after treatment with Ampligen and, based on these early results, the company is working to move forward with a Phase 2 controlled trial.

AIM ImmunoTech reveals positive pilot study data from EAP evaluating Ampligen for treatment of Long COVID

Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of Ampligen for the treatment of Post-COVID conditions

AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

AIM ImmunoTech Inc (NYSE: AIM) reported follow-on data from its published single-center named patient program.  For the study, patients with locally advanced pancreatic cancer (LAPC) or metastatic disease were treated following FOLFIRINOX.

AIM ImmunoTech Posts Additional Patient Data From Pancreatic Cancer Study

AIM ImmunoTech Inc (NYSE:AIM) reported promising follow-on data from its previously published single-center named patient program evaluating its flagship drug candidate Ampligen (rintatolimod) as maintenance therapy for pancreatic cancer. For the study, patients with locally advanced pancreatic cancer or metastatic disease were treated following FOLFIRINOX (a chemotherapy combination used to treat pancreatic cancer), said the company.

AIM ImmunoTech hails positive data from program evaluating Ampligen as maintenance therapy for pancreatic cancer

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and locally advanced pancreatic cancer (LAPC)

AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent Group from Continued Violations of Federal Securities Laws and SEC and Florida Injunctions

AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th at 8:30 AM ET Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD PhD, of Erasmus Medical Center on Monday, July 25th at 8:30 AM ET

AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series

AIM ImmunoTech Inc (NYSE:AIM) announced that it has entered into a lease agreement with the New Jersey Economic Development Authority for a 5,210 square foot research and development (R&D) facility at the state-supported New Jersey Bioscience Center (NJBC). The immuno-pharma company said the incubator at North Brunswick, New Jersey, which is designed for small businesses in the region, is dedicated to life sciences and biotechnology companies, and the NJBC has invested over $70 million in facilities and improvements to its campus.

News for AIM ImmunoTech Inc Stock (AIM)